Increased expression of MYO5A has been observed in several metastatic cell lines, including metastatic colorectal, lung, breast, and prostate cancers, as well as in invasive and metastatic esophageal squamous cell carcinomas [41, 42]. This evidence concerns the gene MYO5A and prostate cancer.